

Oncogenic *ERBB3* Mutations in Human Cancers

Bijay S. Jaiswal, Noelyn M. Kljavin, Eric W. Stawiski, Emily Chan, Chaitali Parikh, Steffen Durinck, Subhra Chaudhuri, Kanan Pujara, Joseph Guillory, Kyle A. Edgar, Vasantharajan Janakiraman, Rolf-Peter Scholz, Krista K. Bowman, Maria Lorenzo, Hong Li, Jiansheng Wu, Wenlin Yuan, Brock A. Peters, Zhengyan Kan, Jeremy Stinson, Michelle Mak, Zora Modrusan, Charles Eigenbrot, Ron Firestein, Howard M. Stern, Krishnaraj Rajalingam, Gabriele Schaefer, Mark A. Merchant, Mark X. Sliwkowski, Frederic J. de Sauvage, and Somasekar Seshagiri*

*Correspondence: sekar@gene.com

<http://dx.doi.org/10.1016/j.ccr.2014.03.030>

(Cancer Cell 23, 603–617; May 13, 2013)

The authors recently became aware of an error in the top panel of Figure 2D showing the expression of ERBB3. An incorrect panel, meant to show ERBB3 expression, was inadvertently included when the figure was originally assembled. The incorrect panel has been replaced below with the correct western blot showing the expression of ERBB3. The correction does not affect the findings reported in the paper. The authors apologize for any confusion the error may have caused.




Figure 2. ERBB3 Mutants Support Transformation and In Vivo Tumor Growth of IMCE Colonic Epithelial Cells